These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23286845)

  • 21. Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients.
    Aziz H; Gill U; Raza A; Gill ML
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):538-43. PubMed ID: 24642690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
    European Association of the Study of the Liver
    Liver Int; 2012 Feb; 32 Suppl 1():2-8. PubMed ID: 22212565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
    Dan YY; Ferrante SA; Elbasha EH; Hsu TY
    Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
    Craxì A; Piccinino F; Ciancio A; Iannacone C; Deodato B; Golotta C; Ascione A
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):388-95. PubMed ID: 24569819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island.
    Karatapanis S; Tsoplou P; Papastergiou V; Vasiageorgi A; Stampori M; Saitis I; Tsitsopoulos E; Lisgos P; Skorda L; Ketikoglou I; Goulis I
    J Med Virol; 2012 Feb; 84(2):223-8. PubMed ID: 22170541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
    J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
    Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
    Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
    Giannini EG; Basso M; Savarino V; Picciotto A
    J Intern Med; 2009 Dec; 266(6):537-46. PubMed ID: 19849774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
    Antaki N; Hermes A; Hadad M; Ftayeh M; Antaki F; Abdo N; Kebbewar K
    J Viral Hepat; 2008 May; 15(5):383-6. PubMed ID: 18086180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hepatitis C virus infection.
    Flamm SL
    JAMA; 2003 May; 289(18):2413-7. PubMed ID: 12746366
    [No Abstract]   [Full Text] [Related]  

  • 31. Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
    Aziz S
    J Coll Physicians Surg Pak; 2012 Oct; 22(10):615-6. PubMed ID: 23058141
    [No Abstract]   [Full Text] [Related]  

  • 32. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
    Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study.
    Ibrahim M; Gomaa W; Ibrahim Y; El Hadad H; Shatat M; Aleem AA; Essawy M; Fouad YM
    J Gastrointestin Liver Dis; 2010 Dec; 19(4):387-92. PubMed ID: 21188329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
    Salmerón J; Casado J; Rueda PM; Lafuente V; Diago M; Romero-Gómez M; Palacios A; León J; Gila A; Quiles R; Rodriguez L; Ruiz-Extremera A
    J Clin Virol; 2008 Apr; 41(4):264-9. PubMed ID: 18221912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough.
    Shiffman ML; Rustgi VK
    Gastroenterology; 2006 Oct; 131(4):1339-41. PubMed ID: 17030201
    [No Abstract]   [Full Text] [Related]  

  • 36. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
    Biermer M; Berg T
    Gastroenterology; 2009 Jul; 137(1):390-1. PubMed ID: 19486953
    [No Abstract]   [Full Text] [Related]  

  • 37. How to optimize HCV therapy in genotype 1 patients: management of side-effects.
    Chopra A; Klein PL; Drinnan T; Lee SS
    Liver Int; 2013 Feb; 33 Suppl 1():30-4. PubMed ID: 23286843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
    Roulot D; Bourcier V; Grando V; Deny P; Baazia Y; Fontaine H; Bailly F; Castera L; De Ledinghen V; Marcellin P; Poupon R; Bourlière M; Zarski JP; Roudot-Thoraval F;
    J Viral Hepat; 2007 Jul; 14(7):460-7. PubMed ID: 17576387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.